Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients

<p>Abstract</p> <p>Background</p> <p>Atherosclerosis is the main cause of mortality and morbidity in end stage renal diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for atherosclerosis, non classical risk factors, such as...

Full description

Bibliographic Details
Main Authors: Rashtchizade Nadereh, Ghorbani Amir, Argani Hassan, Rahbaninobar Mohammad
Format: Article
Language:English
Published: BMC 2004-04-01
Series:Lipids in Health and Disease
Subjects:
Online Access:http://www.lipidworld.com/content/3/1/6
id doaj-acb4e207d307488da5c81eeacd022950
record_format Article
spelling doaj-acb4e207d307488da5c81eeacd0229502020-11-24T20:55:14ZengBMCLipids in Health and Disease1476-511X2004-04-0131610.1186/1476-511X-3-6Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patientsRashtchizade NaderehGhorbani AmirArgani HassanRahbaninobar Mohammad<p>Abstract</p> <p>Background</p> <p>Atherosclerosis is the main cause of mortality and morbidity in end stage renal diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for atherosclerosis, non classical risk factors, such as high lipid peroxidation and low antioxidants, also, are culprit in the pathogenesis.</p> <p>Method</p> <p>We tested lipid peroxidation and total antioxidant levels in forty five stable hyperlipidemic HD males (age range 40–60 years) before, after 45 and 90 days of prescription of 20 mg/day Lovastatin for three months. Malondialdehyde (MDA), as prototype of lipid peroxidation, and total antioxidants (TA) were measured by flourimetric and spectrophotometric assays, respectively.</p> <p>Results</p> <p>Serum triglyceride (Tg) (213.7 ± 112.4 mg/dl vs. 153.4 ± 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 ± 48.3 mg/dl vs. 149.3 ± 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl ± 48.9 vs. 84.8 ± 43.7 mg/d, p = 0.001), VLDL-C (40.7 ± 18.9 mg/dl vs. 30.7 ± 10.9 mg/dl, p = 0.025), MDA (13.1 ± 3.5 nmol/ml vs. 1.27 ± 1 nmol/ml, p = 0.00), TA (0.98 ± 0.17 mmol/l vs. 1.28 ± 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 ± 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy. These changes for HDL, VLDL and Tg after the 3 months were more obvious than 45 days of Lovastatin therapy.</p> <p>Conclusion</p> <p>In HD patients serum lipids and their oxidations are increased. Both of them, quantitatively and qualitatively, are improved by using of Lovastatin. The later would be due to enhance of TA activity.</p> http://www.lipidworld.com/content/3/1/6AtherosclerosisHemodialysisLipid peroxidationAnti oxidants
collection DOAJ
language English
format Article
sources DOAJ
author Rashtchizade Nadereh
Ghorbani Amir
Argani Hassan
Rahbaninobar Mohammad
spellingShingle Rashtchizade Nadereh
Ghorbani Amir
Argani Hassan
Rahbaninobar Mohammad
Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
Lipids in Health and Disease
Atherosclerosis
Hemodialysis
Lipid peroxidation
Anti oxidants
author_facet Rashtchizade Nadereh
Ghorbani Amir
Argani Hassan
Rahbaninobar Mohammad
author_sort Rashtchizade Nadereh
title Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
title_short Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
title_full Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
title_fullStr Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
title_full_unstemmed Effect of Lovastatin on Lipid peroxidation and total antioxidant concentrations in hemodialysis patients
title_sort effect of lovastatin on lipid peroxidation and total antioxidant concentrations in hemodialysis patients
publisher BMC
series Lipids in Health and Disease
issn 1476-511X
publishDate 2004-04-01
description <p>Abstract</p> <p>Background</p> <p>Atherosclerosis is the main cause of mortality and morbidity in end stage renal diseases (ESRD), especially in hemodialysis (HD) patients. In addition the classic risk factors for atherosclerosis, non classical risk factors, such as high lipid peroxidation and low antioxidants, also, are culprit in the pathogenesis.</p> <p>Method</p> <p>We tested lipid peroxidation and total antioxidant levels in forty five stable hyperlipidemic HD males (age range 40–60 years) before, after 45 and 90 days of prescription of 20 mg/day Lovastatin for three months. Malondialdehyde (MDA), as prototype of lipid peroxidation, and total antioxidants (TA) were measured by flourimetric and spectrophotometric assays, respectively.</p> <p>Results</p> <p>Serum triglyceride (Tg) (213.7 ± 112.4 mg/dl vs. 153.4 ± 54.8 mg/dl p = 0.003), serum cholesterol (C) (185.8 ± 48.3 mg/dl vs. 149.3 ± 37.8 mg/dl, p = 0.014), LDL-C (120.1 mg/dl ± 48.9 vs. 84.8 ± 43.7 mg/d, p = 0.001), VLDL-C (40.7 ± 18.9 mg/dl vs. 30.7 ± 10.9 mg/dl, p = 0.025), MDA (13.1 ± 3.5 nmol/ml vs. 1.27 ± 1 nmol/ml, p = 0.00), TA (0.98 ± 0.17 mmol/l vs. 1.28 ± 0.27 mmol/l, p = 0.001) and HDL (24.9+11.1 mg/dl vs. 31.4 ± 7.7 mg/dl, p = 0.007) significantly were changed by 3 months of Lovastatin therapy. These changes for HDL, VLDL and Tg after the 3 months were more obvious than 45 days of Lovastatin therapy.</p> <p>Conclusion</p> <p>In HD patients serum lipids and their oxidations are increased. Both of them, quantitatively and qualitatively, are improved by using of Lovastatin. The later would be due to enhance of TA activity.</p>
topic Atherosclerosis
Hemodialysis
Lipid peroxidation
Anti oxidants
url http://www.lipidworld.com/content/3/1/6
work_keys_str_mv AT rashtchizadenadereh effectoflovastatinonlipidperoxidationandtotalantioxidantconcentrationsinhemodialysispatients
AT ghorbaniamir effectoflovastatinonlipidperoxidationandtotalantioxidantconcentrationsinhemodialysispatients
AT arganihassan effectoflovastatinonlipidperoxidationandtotalantioxidantconcentrationsinhemodialysispatients
AT rahbaninobarmohammad effectoflovastatinonlipidperoxidationandtotalantioxidantconcentrationsinhemodialysispatients
_version_ 1716792078948630528